Novel Therapy Target in Metastatic Prostate Cancer

Although substantial progress in treatments for prostate cancer have been made in the past decades, distant metastasis and drug resistance remained a major cause of prostate cancer-related deaths. The five-year survival rate for men with mPCa was only 30% and all patients with mPCa would inevitably progress to the castration-resistant stage with limited therapeutic chance. In China, the current situation is more worrying, with rapidly increasing PCa incidence and higher proportion of mPCa diagnosed compared with the Western nations (~30% vs ~5%).

Multiomics sequencing provides a promising strategy to discover the underlying molecular basis driving metastasis and resistance and identify the new treatment strategies for patients with mCRPC. The candidate drug target revealed by the multiomics sequencing could be further examined in the organoid and animal models, facilitating the clinical application from basic discovery.

This study can establish a mCRPC research system to find the molecular mechanism and potential intervention targets of mCRPC, thereby paving the way for the discovery of new treatments for mCRPC patients.

Inclusion criteria

• Histologically confirmed prostate cancer
• metastatic disease confirmed by image examination
• Patients who can undergo surgery or biopsy for prostate cancer
• Able to provide informed consent

Exclusion criteria

• Patients diagnosed with other types of cancer besides prostate cancer
• Not accessible to surgery sample
• Patients fail to provide informed consent
• Other situation that researchers think are unsuitable for this study